New research indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt traditional lifestyle plans.
Findings released in a leading medical journal demonstrates that while obese people can lose about a fifth of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Users purchasing these drugs should be aware of the risk of fast weight regain when the therapy concludes," warns expert Dr. Susan Jebb.
This pace of recovery suggests a return to starting mass within about a year and a half.
Analyzing Treatments
The research, which reviewed 37 of studies involving over 9,000 of patients, contrasted the outcomes of these new drugs with other pills.
Researchers point out that people who shed pounds through lifestyle changes alone generally experience a slower creep back—approximately 100 grams monthly—once they finish.
Explaining the Fast Rebound
Doctors believe the way of the injections explains the heightened regain.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians contend that, considering the significant potential of weight regain, the therapy is often life-long.
This perspective is echoed by drug manufacturers, who say that the findings "underscore the chronic character of obesity," similar to managing conditions like hypertension.
Patient Testimonies
Users who have come off the medication report a intense resurgence of cravings.
"It felt as if a trigger flipping and you're instantly extremely hungry," recalled an individual.
This difficulty is worsened if patients have not developed lasting lifestyle or habit changes during therapy.
Significant Interest
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and lasting health benefits likely depends on combined behavioural management.